Resultados de procura - Sean M. Devlin

Limitar resultados
  1. 1
    Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis

    Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis por Ola Landgren, Sean M. Devlin, Mathieu Boulad, Sham Mailankody

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis

    Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis por Mark B. Geyer, Meier Hsu, Sean M. Devlin, Martin S. Tallman, Dan Douer, Jae H. Park

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:
  3. 3
    Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia

    Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia por Samantha Reiss, Larry W. Buie, Nelly G. Adel, Debra A. Goldman, Sean M. Devlin, Dan Douer

    Publicado 2016
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation

    Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation por Bartlomiej Getta, Sean M. Devlin, Ross L. Levine, Maria E. Arcila, Abhinita Mohanty, Ahmet Zehir, Martin S. Tallman, Sergio Giralt, Mikhail Roshal

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis

    Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis por Heather Landau, Melody Smith, Chrystal Ann Landry, Joanne F. Chou, Sean M. Devlin, Hani Hassoun, Christina Bello, Sergio Giralt, Raymond L. Comenzo

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk in Patients With Solid Cancer

    Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk in Patients With Solid Cancer por Stephanie Feldman, Dipti Gupta, Babak B. Navi, Ka-wai Grace Ho, Peter Willeit, Sean M. Devlin, Kelly L. Bolton, Maria E. Arcila, Simon Mantha

    Publicado 2023
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma

    Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma por Craig S. Sauter, Matthew J. Matasar, Jessica Meikle, Heiko Schöder, Gary A. Ulaner, Jocelyn Migliacci, Patrick Hilden, Sean M. Devlin, Andrew D. Zelenetz, Craig H. Moskowitz

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma

    A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma por Nikoletta Lendvai, Patrick Hilden, Sean M. Devlin, Heather Landau, Hani Hassoun, Alexander M. Lesokhin, Ioanna Tsakos, Kaitlyn Redling, Guenther Koehne, David J. Chung, Wendy Schaffer, Sergio Giralt

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy

    T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy por David J. Chung, Katherine B. Pronschinske, Justin A. Shyer, Sneh Sharma, Samantha Leung, Shane A. Curran, Alexander M. Lesokhin, Sean M. Devlin, Sergio Giralt, James W. Young

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia

    TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia por Aaron D. Goldberg, Chetasi Talati, Pinkal Desai, Christopher Famulare, Sean M. Devlin, Noushin Farnoud, David A. Sallman, Jeffrey E. Lancet, Gail J. Roboz, Kendra Sweet, Martin S. Tallman

    Publicado 2018
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice

    Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice por Duncan Purtill, Katherine Smith, Sean M. Devlin, Richard Meagher, Jo‐ann Tonon, Marissa Lubin, Doris M. Ponce, Sergio Giralt, Nancy A. Kernan, Andromachi Scaradavou, Cladd E. Stevens, Juliet N. Barker

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation

    EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation por Miriam Sánchez‐Escamilla, Jessica Flynn, Sean M. Devlin, Molly Maloy, Samira Fatmi, Ana Alarcón Tomás, Silvia Escribano-Serrat, Doris M. Ponce, Craig S. Sauter, Sergio Giralt, Michael Scordo, Miguel‐Angel Perales

    Publicado 2023
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study

    Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study por Salma Afifi, N. Adel, Sean M. Devlin, Elaine Duck, Jill Vanak, Heather Landau, David J. Chung, Nikoletta Lendvai, Alexander M. Lesokhin, Neha Korde, Lilian Reich, Ola Landgren, Sergio Giralt, Hani Hassoun

    Publicado 2016
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation

    Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation por Lee W. Jones, Sean M. Devlin, Molly Maloy, William A. Wood, Sharlynn Tuohy, Noel Espiritu, Jennifer Aquino, Tiffany Kendig, Meghan Michalski, Boglarka Gyurkocza, Wendy Schaffer, Benzar Ali, Sergio Giralt, Ann A. Jakubowski

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia

    Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia por Gerald A. Soff, Yimei Miao, Gemma Bendheim, Jeanette Batista, Jodi V. Mones, Rekha Parameswaran, Cy Wilkins, Sean M. Devlin, Ghassan K. Abou‐Alfa, Andrea Cercek, Nancy E. Kemeny, Debra Sarasohn, Simon Mantha

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy

    Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy por Mark B. Geyer, Isabelle Rivière, Brigitte Sénéchal, Xiuyan Wang, Yongzeng Wang, Terence J. Purdon, Meier Hsu, Sean M. Devlin, Elizabeth Halton, Nicole Lamanna, Jürgen Rademaker, Michel Sadelain, Renier J. Brentjens, Jae H. Park

    Publicado 2018
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation

    Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation por Gunjan L. Shah, Heather Landau, Dory Londono, Sean M. Devlin, Satyajit Kosuri, Alexander M. Lesokhin, Nikoletta Lendvai, Hani Hassoun, David J. Chung, Guenther Koehne, Suresh C. Jhanwar, Ola Landgren, Ross L. Levine, Sergio Giralt

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation

    Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation por Warren Fingrut, Eric Davis, Anne Archer, Samantha Brown, Sean M. Devlin, Melissa Nhaissi, Candice Rapoport, Stephanie Chinapen, Amanda Kelly, Deborah Wells, Andromachi Scaradavou, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Ioannis Politikos, Brian C. Shaffer, Juliet N. Barker

    Publicado 2024
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Autologous transplant remains the preferred therapy for relapsed APL in CR2

    Autologous transplant remains the preferred therapy for relapsed APL in CR2 por Chezi Ganzel, Vikram Mathews, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Deborah Kuk, Sean M. Devlin, Hai‐Lin Wang, M-J Zhang, Daniel J. Weisdorf, Dan Douer, Jacob M. Rowe, Emmanuelle Polge, Jordi Esteve, Arnon Nagler, Mohamad Mohty, Martin S. Tallman

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Favorable Outcomes in Elderly Patients Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma

    Favorable Outcomes in Elderly Patients Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma por Parastoo B. Dahi, Roni Tamari, Sean M. Devlin, Molly Maloy, Valkal Bhatt, Michael Scordo, Jeffrey L. Goldberg, Andrew D. Zelenetz, Paul A. Hamlin, Matthew J. Matasar, Jocelyn Maragulia, Sergio Giralt, Miguel‐Angel Perales, Craig H. Moskowitz, Craig S. Sauter

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: